MS Education Academy honoured for supporting Thalassemia-afflicted kids
Recognising the financial hardships faced by families of Thalassemia-affected children, MS Education Academy has opened admissions free of cost in its institutions—MS Creative School, MS Junior College, and MS Degree College—for such students. So far, hundreds of children have benefited from this initiative and are receiving quality education without any financial burden. In addition to education, MS Education Academy regularly organises Blood Donation Camps to support Thalassemia patients, encouraging its staff and faculty to voluntarily donate blood.
In appreciation of these humanitarian efforts, TSCS honoured the leadership of MS Education Academy with commemorative mementos. The event was graced by Chandrakant Agarwal (President, TSCS India), Ratnavali Kotapalli (Vice President), Dr Suman Jain (Secretary & CEO), M A Aleem Baig (Joint Secretary), Mohammad Ameen (Executive Member), and well-known social media influencer Abu Aimal.
A special citation was also presented during the ceremony, acknowledging the Academy's contribution: 'TSCS appreciates your unwavering support and generous contribution towards the education and empowerment of students affected by Thalassemia and Sickle Cell Anaemia.' Thalassemia-affected students and their parents also attended the event and expressed heartfelt gratitude to MS Education Academy, praising the institution for providing their children with the opportunity to pursue education with dignity and respect—a gesture they described as truly admirable.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New Indian Express
6 days ago
- New Indian Express
Dead chickens spark bird flu fear in Derabish block, put admin on alert
KENDRAPARA: Around 1,500 chickens in some poultry farms of Derabish block have died in the last three days, fuelling fears of bird flu in the region. Chief district veterinary officer (CDVO) of Kendrapara Manoj Patnaik said several chickens died unnaturally between Tuesday and Thursday in poultry farms at Golarahat, Dumuka and nearby villages. The dead chickens were later buried. The two km radius of the area where the chickens died is under surveillance. Officials have also taken precautionary steps to detect sick poultry birds. People of the affected areas have been instructed not to handle the dead chickens without gloves. They were instructed to bury the dead birds by digging deep holes, he said. Patnaik further said there was no reason to panic as the Veterinary department has not detected any H5N1-affected poultry bird in the area. To protect the chickens from Ranikhet disease and bird flu, a large number of poultry birds have been vaccinated. Farmers rearing poultry birds have also been asked to use this opportunity and approach the nearest veterinary dispensaries to get the chickens vaccinated to prevent the viral disease. 'We have already collected samples of blood, stool, tracheal and cloacal of some birds and dead chickens from the poultry farms. The samples have been sent to the Animal Disease Research Institute (ADRI), Cuttack. Several poultry farm owners have been trained to detect sick birds. Poultry farmers have also been advised to take bio-security measures like using aerial disinfectant sprays and administering mandatory vaccines to the birds periodically,' said Patnaik. Nine rapid response teams (RRTs) have been formed in all the blocks of the district. At least 27 veterinary assistant surgeons, livestock inspectors, zilla parishad members and social workers are members of each RRT, he added.
India.com
6 days ago
- India.com
A New HIV Shield: One Shot Every Six Months – Could This Be The Turning Point The World's Been Waiting For?
New Delhi: A new drug that could change the way the world prevents HIV has just received the green signal from the World Health Organization (WHO). Its name is Lenacapavir. And what makes it different? You only need it twice a year. The announcement came from Kigali, Rwanda, where global health experts gathered for the 13th International AIDS Society Conference on July 14. WHO shared new global guidelines to strengthen HIV prevention, and with it, officially recommended Lenacapavir as a key tool – especially for those who face high risk every day. They include sex workers, healthcare workers and people in close contact with HIV-positive individuals. This long-acting drug is not entirely new. The United States approved it earlier. Back in 2022, it was already being used to treat HIV-affected patients. Now, WHO's decision brings it into focus as a prevention method, specifically for pre-exposure prophylaxis (PrEP). WHO Director-General Dr. Tedros Adhanom Ghebreyesus said, 'We still do not have a vaccine for HIV. But this drug, taken only twice a year, is the best new option we have got.' Globally, the HIV burden remains heavy. In 2024 alone, 1.3 million people were infected. Lenacapavir is being hailed as a potential game-changer for global HIV prevention, particularly among communities like sex workers, transgender individuals, people in correctional facilities, men who have sex with men and those who inject drugs, all of whom have been disproportionately affected. Funding for HIV prevention is drying up in many regions. That is why this drug, which works longer and requires fewer doses, feels like a breakthrough. Lenacapavir is a product of U.S. biopharma giant Gilead Sciences. It belongs to a class of medicines called capsid inhibitors, which disrupt multiple steps in the HIV life cycle and help block the virus from replicating. What sets it apart is its long-acting nature. Just two injections a year are enough to offer sustained protection, a significant improvement over daily pills or monthly regimens that are harder to maintain. Compared to daily pills or monthly shots, Lenacapavir offers a simple solution – two injections a year. For those facing daily exposure to risk, this could be the protection they have been waiting for. The need for such interventions has never been more urgent. Over 1.3 million people contracted HIV in 2024 alone, according to WHO data. A large share of these infections occurred in low- and middle-income countries, where preventive care is either unavailable or underfunded. As funding for HIV prevention declines globally, a low-maintenance, highly effective drug like Lenacapavir could help reverse troubling trends. Public health experts say its biannual dosage makes adherence easier, especially for people with limited access to clinics or stigmatised by their communities. While the drug is yet to be rolled out widely, WHO has urged governments and NGOs to accelerate access through partnerships with local health systems. With global focus now shifting toward long-term, low-cost solutions, Lenacapavir offers a ray of hope in a decades-long battle against HIV.
The Hindu
6 days ago
- The Hindu
Thalassemia patients call for standardised tests to reduce transfusion-transmitted infections
On Thursday (July 17, 2025), the Thalassemia Patients Advocacy Group (TPAG), along with legal and health experts, called for the need to strengthen blood safety practices across the country – particularly the need for a standardised test to screen blood donations – to reduce the risk of transfusion-transmitted infections. Following the discussion, held at India International Centre in Delhi on Thursday (July 17, 2025), the group said they would be submitting their recommendations to stakeholders including state and central governments. A 23-year-old Thalassemia patient from Kolkata, present during the discussion, shared her experience of contracting dengue and then testing positive for HIV, to which lack of blood screening could have contributed. She said, 'From the age of two, I have been taking blood transfusions. As a Thalassemia patient, I would require it every 21 days. When I was in Class 8, I contracted dengue and then tested positive with HIV. I don't know for sure if I got it during the blood transfusion or not, but the testing has an important role to play.' At present, Nucleic Acid Testing (NAT), a highly sensitive molecular technique used to screen blood donations for infectious diseases, is used in some hospitals. While it is treated as a gold standard, it is not mandatory across the country. Tuhin A. Sinha, a BJP spokesperson present during the discussion vowed to the group that he would help them take the dialogue forward. Speaking about the importance of NAT testing, he said, 'The Delhi government hospitals have been quick to ensure that it is in place. But one of the important steps should be to develop advocacy for implementing it across the country.' He also suggested incentivising blood donations, saying, 'The more people join the ecosystem, either by way of espousing the idea of donating blood, it will lead to the institutionalisation of systems where checks and balances can be implemented more aggressively.' The discussion was moderated by Anubha Taneja Mukherjee, Member Secretary of TPAG, which is a network of over 10,000 thalassemia patients in the country. She said, 'Based on today's discussion, we will send recommendations to stakeholders including the government, and government agencies.' The recommendations included standardised blood transfusion practises and a mandate for NAT, a national-level blood donation campaign involving influencers, mandatory thalassemia screening for pregnant women. She added that in an attempt to reduce dependence on blood transfusion, hospitals should also make available, novel therapies such as gene therapy. During the discussion, P.C. Sen, a Supreme Court advocate, spoke about the legal and ethical responsibilities of the state and institutions to ensure pathogen-free blood as a constitutional right. Meanwhile, Professor N.K. Ganguly, former Director General of Indian Council of Medical Research (ICMR) suggested an approach that would also involve patients of other blood disorders such as sickle cell anaemia.
